Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ProPhase Labs, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
4.21
9.87
13.1
9.88
14.5
79
123
35
6.77
4.35
Cost of revenue
3.21
7.92
8.35
7.26
9.91
37.1
52
19.4
6.92
2.96
Gross profit
1
1.95
4.78
2.62
4.61
42
70.7
15.6
-0.15
1.38
Research and development
0.36
0.43
0.4
0.33
0.63
0.52
0.65
1.4
0.59
0.11
Selling and marketing
1.7
0.7
1.11
1.04
1.29
General and administrative
2.73
4.81
4.91
4.48
7.5
22.5
34.4
33.4
37.9
19.3
Operating expenses
4.79
5.94
6.42
5.85
8.58
32.2
47.1
36.8
38.5
19.4
Operating income
-2.66
-3.99
-1.63
-3.24
-2.08
9.8
23.6
-21.2
-38.6
-18
Interest expense
0.21
0.05
0.3
1.15
0.76
1.28
3.35
6.93
Interest income
0
0.18
0.17
0.13
0.06
0.64
0.15
0.08
0
Other non-operating income
0.19
0.05
0
0.01
-0.02
-0.17
Pre-tax income
-4.01
-3.66
-1.47
-3.11
-2.31
5.31
22.9
-22.4
-42.3
-23.4
Income tax
-1.42
0.1
0.01
-0.97
4.45
-6.02
7.2
0
Income from continuing operations
-16.4
-49.5
-23.4
Net income
-2.87
40.6
-1.74
-3.15
-2.13
6.27
18.5
-16.8
-53.4
-14.7
EBITDA
-2.23
-3.65
-1.25
-2.84
-1.63
13
28.3
-15.2
-32.4
-13.2
EPS, basic
-1.74
26.68
-1.53
-2.76
-1.84
4.19
11.96
-10.02
-26.68
-1.74
EPS, diluted
-1.74
26.48
-1.53
-2.76
-1.84
4.09
10.43
-10.02
-26.68
-1.74
Shares, basic (weighted)
1.67
1.52
1.11
1.13
1.13
1.48
1.55
1.68
2
8.49
Shares, diluted (weighted)
1.67
1.54
1.11
1.13
1.13
1.8
1.82
1.68
2
8.49
Dividend per share
3.07
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.44
3.17
1.55
0.43
6.82
8.41
9.11
1.61
0.68
0.09
Short-term investments
18.8
6.69
0.93
1.64
8.78
8.33
3.13
3.13
0
Receivables
5.77
1.95
2.97
2.01
3.16
37.7
37.1
35.8
20.1
1.54
Inventory
2.74
1.53
1.9
1.46
3.04
4.6
3.98
2.29
1.14
0.07
Other current assets
0.68
0.48
0.3
0.3
1.24
1.5
2.37
1.96
2.62
1.45
Total current assets
9.63
28.4
18.2
9.95
15.9
61.3
60.8
47.6
30.6
3.15
Property, plant and equipment
3.18
2.74
2.5
2.33
3.58
5.95
7.29
10.3
7.5
2.03
Lease right-of-use assets
4.73
4.4
4.06
4.57
4.12
0
Goodwill
0.9
5.71
5.71
5.23
5.23
3.97
Intangible assets
1.23
10.9
8.48
12.3
9.75
7.17
Other non-current assets
0.24
0.61
1.16
1.16
0.31
0
Total assets
12.8
33.7
20.7
12.3
31.4
89.3
87.6
91.9
63.2
59.9
Accounts payable
2.16
0.56
0.44
0.43
3.77
7.03
5.91
8.64
13.7
Accrued liabilities
0.07
0.17
0.22
0.3
0.3
0.71
1.42
1.95
1.89
Deferred revenue
0.21
0.1
0.17
2.03
2.5
2.38
1.7
1.5
Short-term debt
0
3.21
Total current liabilities
6.84
1.81
4.23
0.93
6.29
15.5
16.1
20.9
32.1
53.1
Long-term debt
0.04
0
2.92
Lease liabilities
4.4
4.2
4.26
4.24
3.76
0
Total liabilities
6.84
1.81
4.23
1.04
20.8
30.7
24
42.5
55.8
56.4
Total debt
0
2.92
Paid-in capital
56.4
58
59.5
60.2
61.7
105
109
119
130
126
Retained earnings
-19.7
20.9
4.53
-1.51
-3.63
2.64
11.8
-5.03
-58.4
-73.1
Treasury stock
-30.7
-47
-47.5
-47.5
-47.5
-48.4
-58
-64
-64
-49.6
Other comprehensive income
-0.08
-0.02
-0
-0.01
-0.18
0.76
-0.3
-0.2
-0.2
Shareholders' equity
5.96
31.8
16.5
11.2
10.6
58.6
63.6
49.4
7.35
3.51
Total equity
5.96
31.8
16.5
11.2
10.6
58.6
63.6
49.4
7.35
3.51
Total liabilities and equity
12.8
33.7
20.7
12.3
31.4
89.3
87.6
91.9
63.2
59.9
Shares outstanding
1.14
1.51
1.59
1.77
2.99
8.97
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-2.87
40.6
-1.74
-3.15
-2.13
6.27
18.5
-16.8
-53.4
-14.7
Depreciation and amortization
0.43
0.34
0.38
0.4
0.45
3.23
4.72
6.05
6.19
4.83
Stock-based compensation
0
0.08
0.63
0.74
1.46
3.18
3.99
3.54
3.64
1.89
Deferred income tax
-1
16.1
0.14
-2.29
-0.14
-7.07
7.15
0
Change in receivables
-1.77
3.83
-1.02
0.94
-1.14
-38.2
-4.5
-0.62
4.74
0.74
Change in inventory
1.6
1.21
-0.37
0.44
-1.28
-1.75
0.7
0.17
1.36
0.31
Change in payables
1.17
-1.59
-0.13
-0.01
3.34
2.45
-1.12
2.86
5.07
-0.72
Cash from operations
-0.47
-2.84
-2.12
-0.84
-2.59
-13.6
28.6
-11.9
-17.5
-8.34
Capital expenditures
-0.65
-0.21
-0.14
-0.23
-1.69
-4.23
-3.92
-2.08
-0.91
0
Acquisitions
-2.5
-9.07
0
-2.9
0
Purchases of investments
-31.7
-13.4
-3.14
-4.56
-21.5
-6.78
-3.82
0
Sales and maturities of investments
12.9
11.1
8.91
15.9
7.12
4.17
3.37
0
Cash from investing
-0.65
21.8
11.9
5.54
-1.02
-19.7
-2.08
-1.37
2.42
0.92
Debt issued
10
Debt repaid
-0.1
Stock issued
1.51
0.34
0
0
3.56
Share buybacks
-16.3
-0.92
-2.15
-0.59
0
Dividends paid
-11.7
-5.82
-4.55
-9.35
0
Cash from financing
-0.1
-16.2
-11.4
-5.82
9.99
35.1
-26
5.76
14.2
6.84
Net change in cash
-1.22
2.73
-1.62
-1.12
6.38
1.84
0.45
-7.5
-0.93
-0.59
Free cash flow
-1.12
-3.05
-2.26
-1.07
-4.28
-17.9
24.6
-14
-18.4
-8.34
Interest paid
0.19
0.05
0.25
1
0.76
0.93
3.11
1.16
Income taxes paid
1.35
0.74
0.1
0
1.7
3
1.13
1.65
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.01 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
16.8%
Gross profit / revenue.
Operating margin
-404.5%
Operating income / revenue.
EBITDA margin
-320.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-568.1%
Pre-tax income / revenue.
Net margin
-583.9%
Net income / revenue.
Operating cash flow margin
-144.1%
Cash from operations / revenue.
Return on assets (ROA)
-39.1%
Net income / average total assets.
Stock-based pay / revenue
41.5%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
84.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-35.8%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-67.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-21.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit CAGR, 3y
-73.0%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
-21.4%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-52.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-61.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-19.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-5.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-11.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
13.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
324.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
66.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
49.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.05x
Current assets / current liabilities.
Quick ratio
0.03x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.27
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.40
Cash from operations / diluted weighted shares.
Book value per share
-$0.22
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.04x
Market cap / revenue.
EV/Sales
0.04x
Enterprise value / revenue.
Earnings yield
-14,406.0%
Net income / market cap (the inverse of P/E).
What was ProPhase Labs, Inc.'s revenue in fiscal 2025?
ProPhase Labs, Inc. reported revenue of $4.3M for fiscal 2025, 35.8% lower than the year before.
Was ProPhase Labs, Inc. profitable in fiscal 2025?
No. It reported a net loss of $14.7M.
How much free cash flow did ProPhase Labs, Inc. generate in fiscal 2025?
Cash from operations of $8.3M minus capital expenditures of $0.0 left free cash flow of -$8.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.